Phase 1 Oral QPX7831 SAD and MAD in Healthy Adults
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This Phase 1 study will assess the safety, tolerability, and pharmacokinetics (PK) of
QPX7831, a beta-lactamase inhibitor, when administered orally in single ascending doses and
in multiple ascending doses to heathy adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Qpex Biopharma, Inc.
Collaborator:
Biomedical Advanced Research and Development Authority